Boston Scientific (BSX) Change in Accured Expenses (2020 - 2026)

Boston Scientific (BSX) has 7 years of Change in Accured Expenses data on file, last reported at -$512.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 32.99% year-over-year to -$512.0 million; the trailing twelve-month figure through Mar 2026 stood at $169.0 million (down 45.13% YoY), and the FY2025 full-year result was $296.0 million, up 21.81% from the prior year.
• Change in Accured Expenses fell to -$512.0 million in Q1 2026, from $285.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $385.0 million in Q4 2024 to a low of -$512.0 million in Q1 2026.
• A 5-year average of -$6.5 million and a median of $23.0 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 5357.14% in 2022 and soared 1573.91% in 2024, its largest moves.
• Tracing BSX's Change in Accured Expenses over 5 years: stood at $335.0 million in 2022, then plunged by 93.13% to $23.0 million in 2023, then soared by 1573.91% to $385.0 million in 2024, then fell by 25.97% to $285.0 million in 2025, then plunged by 279.65% to -$512.0 million in 2026.
• Business Quant data shows BSX's Change in Accured Expenses at -$512.0 million in Q1 2026, $285.0 million in Q4 2025, and $165.0 million in Q3 2025.